<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40343">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02581189</url>
  </required_header>
  <id_info>
    <org_study_id>P15-651</org_study_id>
    <nct_id>NCT02581189</nct_id>
  </id_info>
  <brief_title>Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada</brief_title>
  <acronym>AMBER</acronym>
  <official_title>Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Canada (AMBER)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IST GmbH, Germany</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cato Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <brief_summary>
    <textblock>
      This study seeks to provide evidence of the effectiveness and obtain patient reported
      outcome (PRO) data for the interferon-free ABBVIE REGIMEN ± RBV in participants with chronic
      hepatitis C (CHC) in a real life setting across clinical practice patient populations in
      Canada.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants achieving sustained virological response at week 12 (SVR12)</measure>
    <time_frame>12 weeks after the last dose of study drug</time_frame>
    <description>SVR12 is defined as hepatitis c virus ribonucleic acid (HCV RNA) levels &lt;50 IU/mL 12 weeks after the last dose of study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of the direct-acting antiviral (DAA) dose taken in relation to the target dose of DAA</measure>
    <time_frame>Throughout the study for approximately 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of the ribavirin (RBV) dose taken in relation to the target dose of RBV</measure>
    <time_frame>Throughout the study for approximately 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of missed ribavirin (RBV) treatment days in relation to the target number of RBV treatment days</measure>
    <time_frame>Throughout the study for approximately 36 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Hepatitis C positive participants</arm_group_label>
    <description>Hepatitis C positive participants</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients chronically infected with HCV, receiving the interferon-free ABBVIE REGIMEN
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed, CHC, genotype 1 or 4, treatment-naïve or -experienced participants
             receiving combination therapy with the interferon-free ABBVIE REGIMEN ± RBV

          -  If RBV is co-administered with the ABBVIE REGIMEN, it has been prescribed in line
             with the current local label (with special attention to contraception requirements
             and contraindication during pregnancy)

          -  Participants must voluntarily sign and date a participant authorization to use and/or
             disclose his/her anonymized health data prior to inclusion into the study

        Exclusion Criteria:

          -  Patient participating or intending to participate in a concurrent interventional
             therapeutic trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christina Pelizon, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr John Farley Inc /ID# 155772</name>
      <address>
        <city>Abbotsford</city>
        <zip>V2S 6R6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barrie GI Associates, Inc. /ID# 145360</name>
      <address>
        <city>Barrie</city>
        <zip>L4M 7G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quinte Medical &amp; Surgical Specialists /ID# 144690</name>
      <address>
        <city>Belleville</city>
        <zip>K8N 1E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brampton Civic Hospital /ID# 144530</name>
      <address>
        <city>Brampton</city>
        <zip>L6R 3J7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary /ID# 144547</name>
      <address>
        <city>Calgary</city>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aspen Woods Clinic /ID# 151934</name>
      <address>
        <city>Calgary</city>
        <zip>T3H 0V5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Governors of the University of Calgary /ID# 145357</name>
      <address>
        <city>Calgery</city>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Everett Chalmers Regional Hospital /ID# 144674</name>
      <address>
        <city>Fredricton</city>
        <zip>E3B 5N5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QE II Health Sciences Centre Victoria General Site /ID# 144529</name>
      <address>
        <city>Halifax</city>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster University Medical Centre /ID# 144691</name>
      <address>
        <city>Hamilton</city>
        <zip>L8S 4K1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moncton Hospital /ID# 144693</name>
      <address>
        <city>Moncton</city>
        <zip>E1C 6Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Medicale L'Actuel /ID# 145372</name>
      <address>
        <city>Montreal</city>
        <zip>H2I 4P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Medicale du Quartier Latin /ID# 147593</name>
      <address>
        <city>Montreal</city>
        <zip>H2L 5B1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique de Gastroenterologie et d'Endoscopie Rockland M.D /ID# 144692</name>
      <address>
        <city>Montreal</city>
        <zip>H3P 2V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital, Sir Mortimer B. Davis /ID# 144546</name>
      <address>
        <city>Montreal</city>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center (MUHC) /ID# 144539</name>
      <address>
        <city>Montreal</city>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Gastroenterology Management Ltd /ID# 144527</name>
      <address>
        <city>New Westminster</city>
        <zip>V3L 3W5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott Shulam Medicine Professional Corp /ID# 151273</name>
      <address>
        <city>North Bay</city>
        <zip>P1B 2H3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. A. A. Hamour Inc /ID# 151747</name>
      <address>
        <city>Prince George</city>
        <zip>V2L 2P6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de recherche du CHUQ - CRCEO /ID# 144531</name>
      <address>
        <city>Quebec</city>
        <zip>G1W 4R4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regina Qu'Appelle Health Region /ID# 147920</name>
      <address>
        <city>Regina</city>
        <zip>S4P 0W5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Fingerote Medicine Professional Corporation /ID# 151695</name>
      <address>
        <city>Richmond Hill</city>
        <zip>L4C 1U7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Horizon Health Network /ID# 144684</name>
      <address>
        <city>Saint John</city>
        <zip>E2L4L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saskatchewan Infectious a Disease Care Network /ID# 144695</name>
      <address>
        <city>Saskatoon</city>
        <zip>S7K 0C3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Group Health Centre /ID# 152317</name>
      <address>
        <city>Sault-Ste-Marie</city>
        <zip>P6B 1Y5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUS Hotel Dieu /ID# 144689</name>
      <address>
        <city>Sherbrooke</city>
        <zip>J1G 2E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique de Sante Amitie (CSA) /ID# 152355</name>
      <address>
        <city>St-Jerome</city>
        <zip>J7Z 5B3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hepatitis Center /ID# 147919</name>
      <address>
        <city>Toronto</city>
        <zip>M4V1P7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>True North Medical Centre Inc. /ID# 152349</name>
      <address>
        <city>Toronto</city>
        <zip>M5C 1R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital - University Health Network /ID# 144538</name>
      <address>
        <city>Toronto</city>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>David Moskovitz Medicine Professional Corporation /ID# 149248</name>
      <address>
        <city>Toronto</city>
        <zip>M6C 2C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Liver Centre /ID# 144532</name>
      <address>
        <city>Toronto</city>
        <zip>M6H 3M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LAIR Centre /ID# 144526</name>
      <address>
        <city>Vancouver</city>
        <zip>V5Z 1H2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gordon and Leslie Diamond Health Care Centre /ID# 144688</name>
      <address>
        <city>Vancouver</city>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver Infectious Diseases Centre /ID# 144525</name>
      <address>
        <city>Vancouver</city>
        <zip>V6Z 2C7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GIRI Gastrointestinal Research Institute /ID# 144676</name>
      <address>
        <city>Vancouver</city>
        <zip>V6Z-2K5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Brian Chai Professional Corporation /ID# 157348</name>
      <address>
        <city>Vernon</city>
        <zip>V1T 1W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Percuro Clinical Research, Ltd. /ID# 149247</name>
      <address>
        <city>Victoria</city>
        <zip>V8V 3P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CoolAid Medical Clinic /ID# 145359</name>
      <address>
        <city>Victoria</city>
        <zip>V8W 1M8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Manitoba /ID# 145370</name>
      <address>
        <city>Winnipeg</city>
        <zip>R3E 3P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 6, 2017</lastchanged_date>
  <firstreceived_date>October 19, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Hepatitis C</keyword>
  <keyword>Patient reported outcomes</keyword>
  <keyword>Effectiveness</keyword>
  <keyword>Influence of adherence</keyword>
  <keyword>Genotype 1 or 4</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
